AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10552322 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intra-abdominal pressure (IAP) at 40%
Number of subjects: 10
Study 10552322 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intra-abdominal pressure (IAP) at 80%
Number of subjects: 10
Study 10552322 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing an abdominal belt
Number of subjects: 10
Study 10552322 — intervention group
Group type: COMPARATOR
Intervention: Control (no belt)
Number of subjects: 10
Study 10552322 — intervention group
Group type: COMPARATOR
Intervention: Control (no IAP)
Number of subjects: 10
Study 8563411 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-text search of NEJM
Number of subjects: 0
Study 8563411 — intervention group
Group type: COMPARATOR
Intervention: MEDLINE search
Number of subjects: 0
Study 1685665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 mg remoxipride
Number of subjects: 15
Study 1685665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 100 mg remoxipride
Number of subjects: 15
Study 1685665 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release capsules (A and B) of 100 mg remoxipride
Number of subjects: 15
Study 6124989 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-dergocrine (hydergine)
Number of subjects: 0
Study 6124989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31680269 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine blood glucose assessment at intervention hospitals; automatic requests for glycated haemoglobin (HbA1c) assessment and notification of diabetes services about patients with blood glucose levels of 14 mmol/L or more.
Number of subjects: 133837
Study 31680269 — intervention group
Group type: COMPARATOR
Intervention: Routine blood glucose assessment at control hospitals.
Number of subjects: 133837
Study 27998657 — intervention group
Group type: EXPERIMENTAL
Intervention: HXLPE
Number of subjects: 54
Study 27998657 — intervention group
Group type: COMPARATOR
Intervention: UHMWPE
Number of subjects: 54
Study 27998657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 27585441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low WOMAC Pain group (0-25)
Number of subjects: 202
Study 27585441 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium WOMAC Pain group (26-40)
Number of subjects: 202
Study 27585441 — intervention group
Group type: EXPERIMENTAL
Intervention: High WOMAC Pain group (41-100)
Number of subjects: 202
Study 24082155 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent endurance training (30 s at 100% of max workload, 30 s at rest, for 45 min/day for 12 weeks)
Number of subjects: 100
Study 24082155 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent endurance training
Number of subjects: 100
Study 24082155 — intervention group
Group type: COMPARATOR
Intervention: No exercise advice
Number of subjects: 100
Study 21988478 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy in negative situations
Number of subjects: 292
Study 21988478 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy in positive situations
Number of subjects: 292
Study 19916254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular brachial plexus block with 20 mL of 0.75% ropivacaine
Number of subjects: 60
Study 19916254 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation supraclavicular brachus plexus block with 20 mL of 0.75% ropivacaine
Number of subjects: 60
Study 17454528 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-s rest intervals
Number of subjects: 18
Study 17454528 — intervention group
Group type: COMPARATOR
Intervention: 80-s rest intervals
Number of subjects: 18
Study 15140461 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced print version (simpler language, topic headings, pictures)
Number of subjects: 233
Study 15140461 — intervention group
Group type: COMPARATOR
Intervention: Original written forms
Number of subjects: 233
Study 15140461 — intervention group
Group type: COMPARATOR
Intervention: Narrated videotapes
Number of subjects: 233
Study 15140461 — intervention group
Group type: COMPARATOR
Intervention: Self-paced PowerPoint presentations via laptop computer (bulleted print information, pictures, narration)
Number of subjects: 233
Study 15140461 — intervention group
Group type: COMPARATOR
Intervention: All formats
Number of subjects: 233
Study 12862299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (5 mg/kg as a 30 min infusion, followed by 10 mg/kg during 20 hours in GIKM solution)
Number of subjects: 160
Study 12862299 — intervention group
Group type: COMPARATOR
Intervention: Control group (1000 ml of GIKM alone)
Number of subjects: 160
Study 12862299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 160
Study 9831683 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 8523058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole (450 mg/m2 IV daily for 5 days, then weekly for 48 weeks; levamisole 50 mg orally three times daily for 3 days every 2 weeks for 1 year)
Number of subjects: 318
Study 8523058 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 318
Study 8523058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole
Number of subjects: 318
Study 1744360 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial American cockroach extracts
Number of subjects: 0
Study 1744360 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust extracts
Number of subjects: 0
Study 1744360 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house cockroach whole body extracts
Number of subjects: 0
Study 1744360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal extracts
Number of subjects: 0
Study 7049347 — intervention group
Group type: EXPERIMENTAL
Intervention: AV
Number of subjects: 166
Study 7049347 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 166
Study 7049347 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 166
Study 30272088 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year multifactorial intervention consisting of personal health education and contemporary drug treatments for dyslipidemia and hypertension.
Number of subjects: 1222
Study 30272088 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter vacation time at baseline in the intervention group.
Number of subjects: 1222
Study 30272088 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year intervention improved total CVD risk by 46% in the intervention group.
Number of subjects: 1222
Study 27421905 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training in the ER
Number of subjects: 30
Study 24638071 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 571
Study 24638071 — intervention group
Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 571
Study 22622008 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (60 Gy plus concurrent low-dose carboplatin [30 mg/m² per day, 5 days a week for 20 days])
Number of subjects: 200
Study 22622008 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 200
Study 22622008 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 200
Study 20863761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 504
Study 20863761 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 30 mg
Number of subjects: 504
Study 17656838 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning
Number of subjects: 33
Study 17656838 — intervention group
Group type: COMPARATOR
Intervention: Trial and error learning
Number of subjects: 33
Study 16134756 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (20-80 mg per day)
Number of subjects: 15
Study 12270246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuchamber (metal spacer)
Number of subjects: 17
Study 12270246 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumatic (plastic spacer)
Number of subjects: 17
Study 12270246 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 microg salbutamol
Number of subjects: 17
Study 12270246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9562838 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative communication methods and active screening for illiteracy
Number of subjects: 0
Study 7808837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment, 0.5 mg/kg/d for 1 week
Number of subjects: 23
Study 7808837 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study 7808837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment
Number of subjects: 23
Study 2483328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 6.5 micrograms/kg
Number of subjects: 39
Study 2483328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone 65 micrograms/kg
Number of subjects: 39
Study 2483328 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 39
Study 1141135 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load
Number of subjects: 8
Study 1141135 — intervention group
Group type: COMPARATOR
Intervention: No inspiratory resistive load (unloaded)
Number of subjects: 8
Study 30985667 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with PapacarieMBlue
Number of subjects: 32
Study 30985667 — intervention group
Group type: COMPARATOR
Intervention: Caries removal with a low-speed drill
Number of subjects: 32
Study 28398846 — intervention group
Group type: EXPERIMENTAL
Intervention: TC6 (docetaxel and cyclophosphamide for six cycles)
Number of subjects: 4242
Study 28398846 — intervention group
Group type: COMPARATOR
Intervention: TaxAC (docetaxel, doxorubicin, and cyclophosphamide or other standard AC and taxane combination regimens)
Number of subjects: 4242
Study 28398846 — intervention group
Group type: EXPERIMENTAL
Intervention: TC6 plus bevacizumab (not included in the analysis)
Number of subjects: 4242
Study 26331847 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Availability Scales, Third Edition (Z. Biringen, J. Robinson, & R.N. Emde, 1998) during free play and teaching observations at home
Number of subjects: 226
Study 24081946 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol 145 mg/m(2) every 14 days
Number of subjects: 71
Study 24081946 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol 145 mg/m(2) every 21 days
Number of subjects: 71
Study 20807262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfo-carrabiose
Number of subjects: 0
Study 20807262 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 0
Study 20807262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of caffeine and sulfo-carrabiose
Number of subjects: 0
Study 19904667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 158
Study 16913238 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose administration
Number of subjects: 1077
Study 16913238 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1077
Study 12362264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% erythromycin/5% benzoyl peroxide
Number of subjects: 0
Study 12362264 — intervention group
Group type: COMPARATOR
Intervention: 0.025% tretinoin/erythromycin 4%
Number of subjects: 0
Study 11104215 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 30 microg/kg
Number of subjects: 15
Study 11104215 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 300 microg/kg
Number of subjects: 15
Study 9302209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine + Methimazole (MMI)
Number of subjects: 18
Study 9302209 — intervention group
Group type: COMPARATOR
Intervention: Methimazole (MMI) alone
Number of subjects: 18
Study 8179145 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms.kg‐1
Number of subjects: 60
Study 8179145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8179145 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee intubation
Number of subjects: 60
Study 3297588 — intervention group
Group type: EXPERIMENTAL
Intervention: Destagnation plus radiotherapy
Number of subjects: 425
Study 3297588 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 425
Study 29334878 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS (Individual Placement and Support)
Number of subjects: 2055
Study 29334878 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2055
Study 28274527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol (T+O) 2.5/5µg
Number of subjects: 100
Study 28274527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol (T+O) 5/5µg
Number of subjects: 100
Study 28274527 — intervention group
Group type: COMPARATOR
Intervention: Olodaterol (O) 5µg
Number of subjects: 100
Study 28274527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol (T+O)
Number of subjects: 100
Study 26906165 — intervention group
Group type: EXPERIMENTAL
Intervention: RTH258 4.5 mg
Number of subjects: 194
Study 26906165 — intervention group
Group type: EXPERIMENTAL
Intervention: RTH258 6.0 mg
Number of subjects: 194
Study 26906165 — intervention group
Group type: COMPARATOR
Intervention: ranibizumab 0.5 mg
Number of subjects: 194
Study 23765172 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized nutrition approach
Number of subjects: 223
Study 21609286 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-protein, high-carbohydrate nutrition (0.1/0.4/1.2/0.2 g·kg(‐1)·h(‐1))
Number of subjects: 10
Study 21609286 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control (0.06/1.6/0.2 g·kg(‐1)·h(‐1))
Number of subjects: 10
Study 18937813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular pulse amplitude (OPA) measured with dynamic contour tonometry (DCT)
Number of subjects: 29
Study 18937813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP)
Number of subjects: 29
Study 18937813 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial length (AL)
Number of subjects: 29
Study 18937813 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricle ejection time (LVET)
Number of subjects: 29
Study 18937813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean IOP, AL, and LVET (multiple linear regression analysis)
Number of subjects: 29
Study 16697231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Lactobacillus rhamnosus GR‐1 (1 x 10(9)) and Lactobacillus reuteri RC‐14 (1 x 10(9))
Number of subjects: 125
Study 16697231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16697231 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 125
Study 16697231 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 125
Study 15568329 — intervention group
Group type: EXPERIMENTAL
Intervention: P1 Medium supplemented with 20% SSS
Number of subjects: 349
Study 15568329 — intervention group
Group type: COMPARATOR
Intervention: Cook Medium
Number of subjects: 349
Study 11783604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 41
Study 11783604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 41
Study 9009113 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated water
Number of subjects: 8
Study 9009113 — intervention group
Group type: COMPARATOR
Intervention: Still water
Number of subjects: 8
Study 8024295 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler (half the normal dose)
Number of subjects: 241
Study 8024295 — intervention group
Group type: COMPARATOR
Intervention: Budesonide via Nebuhaler (normal dose)
Number of subjects: 241
Study 3501538 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (FUra)
Number of subjects: 50
Study 3501538 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (FUra) plus high-dose continuous-infusion folinic acid
Number of subjects: 50
Study 31255546 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyetheretherketone (Pk)
Number of subjects: 1
Study 31255546 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium (T)
Number of subjects: 1
Study 31255546 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyetheretherketone with titanium base (Pkt)
Number of subjects: 1
Study 31255546 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant position
Number of subjects: 1
Study 31255546 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant material
Number of subjects: 1
Study 29128208 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pelvic radiation therapy (WPRT)
Number of subjects: 1861
Study 29128208 — intervention group
Group type: COMPARATOR
Intervention: Prostate bed radiation therapy (PBRT)
Number of subjects: 1861
Study 29128208 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 1861
Study 29128208 — intervention group
Group type: COMPARATOR
Intervention: No androgen deprivation therapy (No ADT)
Number of subjects: 1861
Study 29128208 — intervention group
Group type: COMPARATOR
Intervention: WPRT vs PBRT
Number of subjects: 1861
Study 29128208 — intervention group
Group type: COMPARATOR
Intervention: No ADT vs ADT
Number of subjects: 1861
Study 29128208 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant metastases (DM)
Number of subjects: 1861
Study 27459349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multifactorial care with systematic comprehensive geriatric assessment and tailored interventions
Number of subjects: 2283
Study 27459349 — intervention group
Group type: COMPARATOR
Intervention: Current primary care (control group)
Number of subjects: 2283
Study 27459349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multifactorial care
Number of subjects: 2283
Study 24224920 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusions based on platelet mass
Number of subjects: 30
Study 24224920 — intervention group
Group type: COMPARATOR
Intervention: Platelet transfusions based on platelet count
Number of subjects: 30
Study 22352519 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural variations in fundamental frequency (flattened or removed)
Number of subjects: 0
Study 22352519 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting availability of speech envelope and temporal fine structure cues via noisy signal extraction
Number of subjects: 0
Study 22352519 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech envelope
Number of subjects: 0
Study 22352519 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech information transmitted by the envelope
Number of subjects: 0
Study 20466803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate group (n = 8)
Number of subjects: 16
Study 20466803 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate group (n = 8)
Number of subjects: 16
Study 18663341 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection cream containing antioxidant substances with high radical protection factor
Number of subjects: 0
Study 18663341 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15537673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness measurement in AD patients
Number of subjects: 36
Study 15537673 — intervention group
Group type: COMPARATOR
Intervention: Cortical thickness measurement in controls
Number of subjects: 36
Study 15537673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness measurement over time
Number of subjects: 36
Study 14511552 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum infections
Number of subjects: 243
Study 14511552 — intervention group
Group type: EXPERIMENTAL
Intervention: P. vivax infections
Number of subjects: 243
Study 14511552 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe malaria requiring intravenous quinine therapy
Number of subjects: 243
Study 14511552 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of malarial infection
Number of subjects: 243
Study 14511552 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean parasite counts for P. falciparum
Number of subjects: 243
Study 14511552 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean parasite counts for P. vivax
Number of subjects: 243
Study 14511552 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of parasitaemia in the village
Number of subjects: 243
Study 10710132 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (cigarette)
Number of subjects: 16
Study 10710132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 16
Study 10710132 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study 8648387 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy alone
Number of subjects: 60
Study 8648387 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy with mantle or mediastinal RT
Number of subjects: 60
Study 8648387 — intervention group
Group type: COMPARATOR
Intervention: ABVD chemotherapy
Number of subjects: 60
Study 8398189 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic digoxin
Number of subjects: 50
Study 8398189 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic digoxin (control)
Number of subjects: 50
Study 8398189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 50
Study 3950878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-Gentamicin
Number of subjects: 123
Study 3950878 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 123
Study 28971727 — intervention group
Group type: EXPERIMENTAL
Intervention: DSL prescription
Number of subjects: 232
Study 28971727 — intervention group
Group type: COMPARATOR
Intervention: NAL prescription
Number of subjects: 232
Study 28971727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DSL and NAL prescriptions
Number of subjects: 232
Study 27496577 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis and BTX‐A injections in the temporal and masseter muscles (Group A)
Number of subjects: 20